AES-350
AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research[1].
Product Specifications
CAS Number
[847249-57-4]
UNSPSC
12352005
Hazard Statement
H228, H315, H319
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/aes-350.html
Purity
99.30
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NO)C1=CC=C(NC(C2=CC=C(C(C)(C)C)C=C2)=O)C=C1
Molecular Formula
C18H20N2O3
Molecular Weight
312.36
Precautions
H228, H315, H319
References & Citations
[1]Andrew E Shouksmith, et al. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC11; HDAC3; HDAC6
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Human Single-minded homolog 2 (SIM2)), partial
Recombinant Human Single-minded homolog 2 (SIM2)), partial
Recombinant Human Single-minded homolog 2 (SIM2)), partial
Recombinant Human Single-minded homolog 2 (SIM2)), partial